ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2998

Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices – a Prospective Study

Thomas Frauenfelder1, Anna Winklehner1, Thi Dan Linh Nguyen1, Rucsandra Dobrota2,3, Stephan Baumüller1, Britta Maurer2 and Oliver Distler2, 1Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, 2Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Computed tomography (CT), interstitial lung disease, Lung Disease, scleroderma and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis

Session Type: Abstract Submissions (ACR)

Background/Purpose Early diagnosis of interstitial lung disease (ILD), currently the main cause of death in systemic sclerosis (SSc), is needed. The gold standard is high resolution computed tomography (HRCT) of the chest, but regular screening faces the risk of increased radiation exposure. We perform a prospective validation of a dedicated, 9-slice HRCT protocol with reduced radiation dose for the detection of ILD in patients with SSc.

Methods We analysed 170/205 consecutive patients with SSc. Whole chest HRCT, serving as standard of reference, and the reduced HRCT with 9 slices allocated according to a basal-apical gradient were obtained. ILD presence, extent (>or<20%) and diagnostic confidence were assessed. The reduced CT was independently analysed by 2 blinded radiologists, who also evaluated image quality. The effective radiation doses and the test performance parameters of the reduced HRCT were calculated.

Results The study cohort included early (n=66), limited cutaneous SSc (n=66) and diffuse cutaneous SSc (n=34) patients, with a median disease duration of 60 months (Q1;Q3 28,120). Standard chest HRCT showed ILD in 77/170 patients. With the reduced HRCT, 68/77 cases with ILD were identified (sensitivity 88.3%, both readers). The accuracy (91.8%-reader1, 94.7%-reader2), diagnostic confidence (98.8%-reader1, 95.3%-reader2) and image quality rates were high (Table 1). Missed cases were exclusively borderline to minimal ILD on standard CT. Minimal ILD was correctly quantified in 73.1% (reader1) /71.2% (reader2) and extensive ILD in 88% (reader 1) /100% (reader 2) (Table 2). Importantly, the reduced CT had a significantly lower radiation dose. The mean DLP (effective dose) was only 5.66±4.46 mGycm (0.08±0.06 mSv), compared with the standard protocol dose of 149.00±95.90 mGycm (2.09±1.34 mSv).

The presence of associated lung pathology was also assessed. In this cohort, 8/10 lung nodules were also detected on the reduced CT (all <6 mm diameter and stable at follow-up).

Table 1.Estimated accuracy and diagnostic certainty in detecting ILD on reduced CT scans

 

Reader 1

Reader 2

Sensitivity (95% CI)

88.3% (78.5%-94.2%)

88.3% (78.5%-94.2%)

Specificity  (95% CI)

94.6% (87.3%-98.0%)

100% (95.1%-100%)

Accuracy

91.8%

94.7%

NPV (95% CI)

90.7% (82.7%-95.4%)

91.2% (83.5%-95.6%)

High diagnostic   confidence*

98.8%

95.3%

* degree of confidence score 1 or 2 (i.e. 1 =   fully confident; 2 = probably confident); CI = Confidence interval (in   parenthesis), NPV = Negative predictive value

 

Table 2.Estimated extent of ILD in standard CT and reduced CT scans

Lung involvement in standard CT

Estimated extent in reduced CT

No ILD

Minimal (<20%)

Extensive (>20%)

Indeterminate

Reader 1/2

Reader 1/2

Reader 1/2

Reader 1/2

Minimal (<20%)   

n = 52

n = 9/9

n = 38/37*

n = 5/6

n = 0/0

Extensive (>20%) 

n = 25

n = 0/0

n = 3/0

n=22/25*

n = 0/0

ILD was present in 77 patients in standard CT. *Correctly estimated extent in reduced CT as  compared to standard CT.

Conclusion The above-described reduced chest HRCT protocol reliably detects even mild SSc-ILD in clinical practice, with the advantage of a much lower radiation dose compared to standard whole chest HRCT. This makes it an attractive protocol for periodical screening for ILD in SSc.


Disclosure:

T. Frauenfelder,
None;

A. Winklehner,
None;

T. D. L. Nguyen,
None;

R. Dobrota,

Pfizer Inc,

2;

S. Baumüller,
None;

B. Maurer,
None;

O. Distler,

Actelion, Pfizer, Ergonex, BMS, Bayer, United BioSource Corporation, Roche/Genentech, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4D Science, Active Biotec, Sinoxa, Sanofi-Aventis, Serodapharm, GSK, Epipharm,

5,

Actelion, Pfizer, Ergonex, Sanofi-Aventis,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/screening-for-interstitial-lung-disease-in-systemic-sclerosis-performance-of-high-resolution-computed-tomography-with-limited-number-of-slices-a-prospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology